ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
EPHB4	2050	12562648	-	-	-	-	-	102	37 to 91	66.1	Department of Obsterics and Gynecology; University of Bern	IA (n=11); IB (n=53); IC (n=24); IIA (n=2); IIB (n=4); IIIA (n=2); IIIC (n=6)	1 (n=18); 2 (n=75); 3 (n=9)	[1] A drastic increase (P <0.0001) in the number of EphB4 protein-expressing glandular epithelial cells in the majority of hyperplasias and carcinomas. Moreover; there is a statistically highly significant positive correlation between EphB4 expression and post-menopausal stage of the patient (P = 0.007). [2] EphB4 is an early indicator of malignant development and; thus; EphB4 may represent a potent tool for diagnosis and therapeutic intervention.	Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype	Modern Pathology	15(10):1032-7	2002
EPHB4	2050	17108150	-	Up regulation/ Over expression/High expression	-	Prognostic Marker	-	-	35 to 79	-	Department of Obstetrics and Gynecology; Gifu University School of Medicine; Japan	I (n=25); II (n=21); III (n=22)	1 (n=24); 2 (n=22); 3 (n=22)	[1] EphB4 is overexpressed during the tumor advancement as dedifferentiation and myometrial invasion. Therefore; EphB4 might work on tumor advancement and may be recognized as a novel prognostic indicator for uterine endometrial cancers. [2] EphB4 histoscores are highly correlated with EphB4 mRNA levels(r = 0.615; P < 0.01). Both the histoscores and mRNA levels of EphB4 significantly increased with clinical stages (I < II < III; P < 0.01); dedifferentiation (G(1) < G(2) < G(3); P < 0.01) and myometrial invasion (P < 0.05) in uterine endometrial cancers.	Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.	Annals of Oncology	18(3):485-90	2007